AHFS Drug Information (AHFS DI) is a leading source of evidence-based drug information.
AHFS DI is a dependable, comprehensive and objective database for FDA approved drug products. Inclusion of evidence-based data on labelled and unlabelled drug use makes this a valuable reference for healthcare professionals seeking to provide their patients with safe and effective therapy.
AHFS DI is published by the American Society of Health-System Pharmacists (ASHP).
Sales and UpgradesContent Updates
Comprehensive: Highly detailed monographs with extensive information on the chemistry and clinical application of all FDA approved drugs
Evidence-based: Built on evidence from primary sources and peer reviewed by over 500 pharmacists, physicians and healthcare professionals
Dependable: Fast and easy access to content that is revalidated, revised and updated regularly as new information arrives
Objective: The information is compiled without any influence from manufacturers, insurers, regulators or other interested parties
This update contains 4 new monographs and 25 revised monographs.
New monographs: Omaveloxolone; Pegcetacoplan (EENT); Sparsentan; Velmanase Alfa-tycv.
Revised monographs: Ambrisentan; Apixaban; Belimumab; Bosentan; Dabigatran; Dupilumab; Emicizumab-kxwh; Epoprostenol; Iloprost; Inebilizumab-cdon; Macitentan; Misoprostol; Naloxone; Nitric Oxide; Omidenepag Isopropyl; Pneumococcal Vaccine; Riociguat; Rivaroxaban; Selexipag; Sildenafil; Smallpox and Mpox Vaccine Live; Tadalafil; Tecovirimat; Treprostinil; Warfarin.
This update contains 4 new monographs and 18 revised monographs.
New monographs: Daprodustat; Elacestrant; Pirtobrutinib; Sodium Thiosulfate (Protective Agent).
Revised monographs: Apalutamide; Corticosteroids General Statement; Deucravacitinib; Dextromethorphan and Bupropion; Duvelisib; Fingolimod; Interferon Beta; Molnupiravir; Niraparib; Nirmatrelvir and Ritonavir; Roflumilast (Topical); Satralizumab-mwge; Selinexor; Sodium Thiosulfate (Antidote); Terlipressin; Tocilizumab; Vedolizumab; Vosoritide.
This update contains 9 new monographs, 13 revised monographs, 61 discontinued monographs and 2 new MedWatch alerts.
New monographs: Adagrasib; Anacaulase (Topical); Fecal microbiota, live; Futibatinib; Lecanemab; Lenacapavir Sodium; Mosunetuzumab-axgb; Sirolimus Protein-bound Particles; Ublituximab.
Revised monographs: Amivantamab-vmjw; Evolocumab; Idelalisib; Ketamine; Levoketoconazole; Lumacaftor and Ivacaftor; Lumateperone; Mifepristone; Pneumococcal Vaccine; Rolapitant; Tezacaftor and Ivacaftor; Trametinib Dimethyl Sulfoxide; Vutrisiran.
Discontinued monographs: Abametapir; Acrivastine; Alefacept; Altretamine; Amifampridine; Aminohippurate; Aurothioglucose/Gold Sodium Thiomalate; Belantamab Mafodotin-blmf; Benzyl Alcohol; Benzyl Benzoate; Butabarbital; Cefditoren; Ceftibuten; Cellulose Sodium Phosphate; Collagenase Clostridium Histolyticum-aaes; Denileukin; Desirudin; Doripenem; Emedastine; Eprosartan; Etidronate; Fluoxymesterone; Gallium Nitrate; Guanabenz; Hexachlorophene; Hydrogen Peroxide 40%; Hydroxyethyl Starch 130/0.4; Indacaterol; Ingenol Mebutate; Invert Sugar; Isoxsuprine; Liotrix; Lorcaserin; Lutropin Alfa; Maprotiline; Mechlorethamine; Mequinol/Tretinoin; Metaproterenol; Methyclothiazide; Mipomersen; Monobenzone; Morrhuate Sodium; Nedocromil; Nesiritide; Ofatumumab; Panobinostat; Pemirolast; Propantheline; Rimexolone; Saquinavir; Secobarbital; Sodium Thiosalicylate; Tegaserod; Teniposide; Ticlopidine; TOLAZamide; TOLBUTamide; Tolmetin; Umbralisib; Urea 40-50% Injection; Zoster Vaccine Live.
New Medwatch alerts on the following monographs: Blinatumomab; Tixagevimab and Cilgavimab.
This update contains 7 new monographs, 18 revised monographs and 2 new MedWatch alerts.
New monographs: Antihemophilic Factor (recombinant), PEGylated; Cysteamine; Olutasidenib; Teclistamab; Teplizumab-mzwv; Tirzepatide; Varenicline.
Revised monographs: Alirocumab; Antihemophilic Factor (recombinant), PEGylated-aucl; Avacopan; Baricitinib; Bempedoic Acid; Elexacaftor, Tezacaftor, and Ivacaftor; Ibrexafungerp; Lonafarnib; Mobocertinib; Molnupiravir; Ocrelizumab; Palivizumab; Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf; Pimavanserin; Pirfenidone; Teriflunomide; Tixagevimab and Cilgavimab; Voclosporin.
New MedWatch alerts on the following monographs: Bebtelovimab; Denosumab.
This update contains 12 new monographs, 15 revised monographs and 1 new MedWatch alert.
New monographs: Chloroprocaine (EENT); Eflapegrastim; Emtricitabine and Tenofovir Alafenamide; Emtricitabine and Tenofovir Disoproxil Fumarate; Mirvetuximab Soravtansine-gynx; Mitapivat; Sodium Phenylbutyrate and Taurursodiol; Sutimlimab; Tapinarof; Tremelimumab; Vonoprazan and Amoxicillin; Vonoprazan, Clarithromycin, and Amoxicillin.
Revised monographs: Abrocitinib (Topical); Asciminib; COVID-19 Vaccine (Moderna); COVID-19 Vaccine (Novavax); COVID-19 Vaccine (Pfizer-BioNTech); Darolutamide; Empagliflozin; Fostemsavir; Imipenem, Cilastatin Sodium, and Relebactam; Ivacaftor; Lasmiditan; Margetuximab; Naltrexone and bupropion; Peginterferon Beta-1a; Ropeginterferon Alfa-2b.
New MedWatch alert on the following monograph: Belantamab Mafodotin-blmf.
This update contains 4 new monographs and 21 revised monographs.
New monographs: Omidenepag Isopropyl; Sodium Nitrite; Sodium Thiosulfate; Tebentafusp.
Revised monographs: Abiraterone; Brexanolone; Buprenorphine; Capecitabine; Ceritinib; COVID-19 Vaccine (Moderna); COVID-19 Vaccine (Pfizer-BioNTech); Dabrafenib; Dalfampridine; Enasidenib; Influenza Vaccine Live Intranasal; Influenza Vaccine Recombinant; Influenza Virus Vaccine Inactivated; Lapatinib; Lusutrombopag; Mifepristone; Misoprostol; Oxaliplatin; Tezepelumab-ekko; Vancomycin; Venetoclax.
